STT3A/B-IN-1
STT3A/B-IN-1 is an orally active STT3A/B inhibitor with antiviral activity. STT3A/B-IN-1 upregulates DERL3 gene expression levels. STT3A/B-IN-1 is promising for research of viral diseases, including cancer and neurodegenerative disorders[1].
Product Specifications
CAS Number
3067184-99-7
UNSPSC
12352005
Target
Virus Protease
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Cancer; Infection; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/stt3a-b-in-1.html
Purity
99.15
Smiles
C[S@@](=N)(C1=CC=C(C(C2=CC3=C(C=CC=C3)N2)=C1)N4CC[C@@H](C4)O)=O
Molecular Formula
C19H21N3O2S
Molecular Weight
355.45
References & Citations
[1]Pero JE, et al. Discovery of Potent STT3A/B Inhibitors and Assessment of Their Multipathogen Antiviral Potential and Safety. J Med Chem. 2024 Aug 22;67 (16) :14586-14608.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400965-500 1x 500 µL
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (VU-11D1), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680218-100 1x 100 µL
CD100 (Semaphorin-4D) (A8), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
